Sidabenamide combined with navulizumab showed the potential to become a new standard treatment for advanced melanoma, reducing the risk of disease progression by 27% in the global phase 3 trial.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.